IMMUNE & THYMIC / FAQ
Questions From the Research Record
Direct, citation-anchored answers to the questions readers most often bring to thymulin and KPV.
What is thymulin?
Thymulin is a nine-amino-acid hormone (a nonapeptide) made exclusively by cells in the thymus, the gland behind the breastbone where T cells mature. It only becomes biologically active once it binds one zinc ion per molecule — the zinc-free peptide is essentially inactive [5][7]. Once zinc-bound, thymulin helps direct T-cell differentiation and calms inflammatory signaling through the NF-kB pathway [3]. It is not an FDA-approved medicine and is available only as a research peptide.
What is thymulin peptide?
As a peptide, thymulin is the linear chain pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, molecular formula C33H54N12O15 [5]. The name "thymulin" specifically refers to the zinc-bound, biologically active form of this chain; the same sequence without bound zinc is sometimes called FTS (facteur thymique serique) in its inactive state — a distinction established when researchers used a metal chelator to strip zinc from the peptide and abolish its activity, then restored it by adding zinc back [7].
Is thymulin the same as serum thymic factor (FTS)?
Closely related but not identical in every context. "Serum thymic factor" (FTS) was the original name for the peptide before its zinc dependency was characterized. The 1982 study that identified zinc as essential to the peptide's activity proposed the name "thymulin" specifically for the zinc-bound, active form (FTS-Zn), reserving "FTS" for the peptide chain itself regardless of zinc status [7]. In current usage the two names are largely used interchangeably, but technically "thymulin" denotes the active, zinc-bound state.
How is thymulin different from thymosin alpha-1?
Thymulin and thymosin alpha-1 are both thymus-associated peptides but are chemically and pharmacologically distinct compounds, and consumer sources online frequently and incorrectly conflate the two. Thymulin is a nine-amino-acid, zinc-dependent nonapeptide produced by thymic epithelial cells with a defined role in T-cell differentiation and NF-kB-mediated anti-inflammatory signaling [3][5]. Thymosin alpha-1 is a different, longer thymic peptide studied in a separate body of literature. This corpus covers only thymulin; it does not extend thymulin's findings to thymosin alpha-1 or to thymalin, a third and also-distinct bovine thymic extract sometimes confused with both.
What is KPV peptide?
KPV is a three-amino-acid peptide (a tripeptide) — lysine, proline, valine — corresponding to residues 11-13, the C-terminal end, of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH's anti-inflammatory activity but not the pigment-related (melanogenic) activity of the full hormone [12]. It is not FDA-approved and has no published human clinical trials; the entire supporting literature is in vitro and murine [10].
What does KPV peptide do?
In laboratory and animal studies, KPV suppresses two related inflammatory signaling pathways — NF-kB and MAP kinase — and reduces secretion of pro-inflammatory cytokines including IL-1beta and TNF-alpha [10]. In the gut specifically, it is taken up into intestinal epithelial cells via the PepT1 transporter, which is upregulated in inflamed tissue and effectively concentrates the peptide where inflammation is occurring [10]. Across several murine colitis models, KPV treatment produced earlier recovery, reduced inflammatory-cell infiltrate, and restored gut tight-junction proteins [8][11].
What is KPV peptide used for?
In the published literature, KPV has been studied almost exclusively for gut inflammation — specifically colitis models induced by DSS (dextran sulfate sodium) and TNBS in mice. Recent studies have paired KPV with delivery technologies to get it into inflamed colon tissue intact: hyaluronic-acid-functionalized nanoparticles in a hydrogel [9], and a PepT1-targeted nanodrug combining KPV with the immunosuppressant FK506 [8]. There is no published research on KPV for any indication outside these inflammatory-bowel-disease models, and no human trials of any kind.
What is KPV peptide good for?
Based on the available preclinical evidence, KPV is studied as an anti-inflammatory agent — specifically for calming the excessive immune activation seen in inflammatory bowel disease models. It suppresses NF-kB and MAP-kinase signaling in intestinal cells [10] and has reduced colitis severity across several independent mouse studies [8][9][11]. Because every study is in vitro or murine, and because KPV is a fragile peptide still being engineered into stable delivery formulations, none of this establishes what KPV does in a person; it describes what has been observed so far in cells and mice.